Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paradigm Genetics gets funds for liver marker work:

This article was originally published in Clinica

Executive Summary

Paradigm Genetics has received a $742,000 award in the US to find biochemicals in urine, serum and liver tissue that predict the early onset of drug-induced liver injury. Biomarkers discovered by the firm could provide diagnostics that help pharmaceutical companies better assess drug candidate safety and that might also enable physicians to more effectively diagnose and treat disease. Under the award, from the National Institutes of Health, Paradigm will conduct preclinical studies on three compounds known to cause liver damage, using mass spectrometry to measure changes in hundreds of small molecular weight biochemicals that may be linked to liver toxicity.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058821

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel